Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Prostate Cancer

  Free Subscription


Articles published in BJU Int

Retrieve available abstracts of 127 articles:
HTML format



Single Articles


    December 2022
  1. BRAIDE K, Kindblom J, Thellenberg Karlsson C, Stattin P, et al
    Risk of severe late toxicity after radiotherapy following radical prostatectomy - a nationwide study.
    BJU Int. 2022;130:799-808.
    PubMed     Abstract available


    November 2022
  2. HOGENHOUT R, Osses DF, Alberts AR, Buizer-Rijksen HG, et al
    Shifting risk-stratified early prostate cancer detection to a primary healthcare setting.
    BJU Int. 2022 Nov 21. doi: 10.1111/bju.15933.
    PubMed     Abstract available


  3. KELLY R, Jensen A, Karunaratna N, Wong S, et al
    PSMA PET-CT use prior to systemic therapy in metastatic Castration-Resistant Prostate Cancer (mCRPC).
    BJU Int. 2022 Nov 13. doi: 10.1111/bju.15930.
    PubMed    


  4. DOAN P, Counter W, Papa N, Sheehan-Dare G, et al
    Synchronous versus independent reading of PSMA-PET and MRI to improve diagnosis for prostate cancer.
    BJU Int. 2022 Nov 13. doi: 10.1111/bju.15929.
    PubMed     Abstract available


  5. CUSSENOT O, Cancel-Tassin G, Comperat E, Benbouzid S, et al
    Total pelvic exenteration surgery for loco-regionally advanced prostate cancer, is it justifiable?
    BJU Int. 2022;130:582-585.
    PubMed    


  6. VAN DER SLOT MA, den Bakker MA, Tan TSC, Remmers S, et al
    NeuroSAFE in radical prostatectomy increases the rate of nerve-sparing surgery without affecting oncological outcome.
    BJU Int. 2022;130:628-636.
    PubMed     Abstract available


  7. LAWRENTSCHUK N
    Funding of all issues related to prostate cancer treatment should be a priority and have equal access - a key to survivorship.
    BJU Int. 2022;130 Suppl 3:4.
    PubMed    


  8. YAXLEY WJ, Mackean J, Desai DJ, Tsang G, et al
    Oncological and urinary outcomes following low-dose-rate brachytherapy with a median follow-up of 11.8 years.
    BJU Int. 2022;130 Suppl 3:40-45.
    PubMed     Abstract available


  9. ROBERTS MJ, Chatfield MD, Hruby G, Nandurkar R, et al
    Event-free survival after radical prostatectomy according to prostate-specific membrane antigen-positron emission tomography and European Association of Urology biochemical recurrence risk groups.
    BJU Int. 2022;130 Suppl 3:32-39.
    PubMed     Abstract available


    September 2022
  10. ELDRED-EVANS D, Connor MJ, Bertoncelli Tanaka M, Bass E, et al
    The Rapid Assessment for Prostate Imaging and Diagnosis (RAPID) prostate cancer diagnostic pathway.
    BJU Int. 2022 Sep 22. doi: 10.1111/bju.15899.
    PubMed     Abstract available


  11. VEERMAN H, Donswijk M, Bekers E, Bodar YJL, et al
    The Oncological Characteristics of Non-PSMA-Expressing Primary Prostate Cancer on preoperative PSMA PET/CT.
    BJU Int. 2022 Sep 19. doi: 10.1111/bju.15896.
    PubMed    


  12. EHRET F, Hofmann T, Furweger C, Kufeld M, et al
    Single-fraction PSMA-PET- and multiparametric MRI-guided SBRT for Prostate Cancer Local Recurrences.
    BJU Int. 2022 Sep 17. doi: 10.1111/bju.15894.
    PubMed     Abstract available


  13. HAEUSER L, Nguyen DD, Trinh QD
    Prostate cancer and kidney transplantation - exclusion or coexistence?
    BJU Int. 2022 Sep 12. doi: 10.1111/bju.15074.
    PubMed    


  14. ORRASON AW, Styrke J, Garmo H, Stattin P, et al
    Evidence of cancer progression as the cause of death in men with prostate cancer in Sweden.
    BJU Int. 2022 Sep 11. doi: 10.1111/bju.15891.
    PubMed     Abstract available


  15. ICZKOWSKI KA, Molina M, Egevad L, Bostwick DG, et al
    Low-Grade Prostate Cancer Should Still be Labeled Cancer.
    BJU Int. 2022 Sep 9. doi: 10.1111/bju.15886.
    PubMed    


  16. ONG S, Chen K, Grummet J, Yaxley J, et al
    Guidelines of guidelines: Focal therapy for prostate cancer, is it time for consensus?
    BJU Int. 2022 Sep 9. doi: 10.1111/bju.15883.
    PubMed     Abstract available


  17. MEIJER D, Ettema RH, van Leeuwen PJ, van der Kwast TH, et al
    The prognostic value of lymph node staging with prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) and extended pelvic lymph node dissection in node-positive patients with prostate cancer.
    BJU Int. 2022 Sep 7. doi: 10.1111/bju.15881.
    PubMed     Abstract available



  18. Updates on bladder, kidney and prostate cancers.
    BJU Int. 2022;130:275-276.
    PubMed    


  19. RAHOTA RG, Salin A, Gautier JR, Almeras C, et al
    A prehabilitation programme implemented before robot-assisted radical prostatectomy improves peri-operative outcomes and continence recovery.
    BJU Int. 2022;130:357-363.
    PubMed     Abstract available


    August 2022
  20. EXTERKATE L, Wegelin O, Barentsz JO, van der Leest MG, et al
    Incidence of significant prostate cancer after negative MRI and systematic biopsy in the FUTURE trial.
    BJU Int. 2022 Aug 22. doi: 10.1111/bju.15876.
    PubMed     Abstract available


  21. SCHNEIDER A, Bulafka J, Arisi MF, Li L, et al
    Case of the month from the Thomas Jefferson Sidney Kimmel medical college, Philadelphia, USA. Prostatic abscess and advanced prostate cancer: considering malignancy in the differential diagnosis.
    BJU Int. 2022;130:181-185.
    PubMed    


    July 2022
  22. WILLIAMS IS, Perera S, Murphy DG, Corcoran NM, et al
    Active surveillance versus enzalutamide for low-risk prostate cancer- was it really a trial we needed?
    BJU Int. 2022 Jul 25. doi: 10.1111/bju.15860.
    PubMed    


  23. RUSHWORTH LK, Loveridge C, Salji M, MacLeod M, et al
    Phase II Proof of Concept Study of Atorvastatin in Castration Resistant Prostate Cancer.
    BJU Int. 2022 Jul 18. doi: 10.1111/bju.15851.
    PubMed     Abstract available



  24. FDA approves new agent for the treatment of metastatic prostate cancer.
    BJU Int. 2022;130:3-4.
    PubMed    


  25. PARRY MG, Skolarus TA, Nossiter J, Sujenthiran A, et al
    Urinary incontinence and use of incontinence surgery after radical prostatectomy: a national study using patient-reported outcomes.
    BJU Int. 2022;130:84-91.
    PubMed     Abstract available


  26. SETIA SA, Smith J, Cendo D, Yoder J, et al
    Outcomes of freehand transperineal prostate biopsy with omission of antibiotic prophylaxis.
    BJU Int. 2022;130:54-61.
    PubMed     Abstract available


    June 2022
  27. DJURHUUS SS, Simonsen C, Toft BG, Thomsen SN, et al
    Exercise Training to Increase Tumor NK Cell Infiltration in Men with Localized Prostate Cancer: an RCT.
    BJU Int. 2022 Jun 26. doi: 10.1111/bju.15842.
    PubMed     Abstract available


  28. AGGARWAL A, Han L, Tree A, Lewis D, et al
    Impact of centralisation of prostate cancer services on the choice of radical treatment.
    BJU Int. 2022 Jun 20. doi: 10.1111/bju.15830.
    PubMed     Abstract available


  29. SUSHENTSEV N, Barrett T, Warren AY, Gnanapragasam VJ, et al
    How and when should radiologists report T-staging on MRI in patients with prostate cancer?
    BJU Int. 2022 Jun 13. doi: 10.1111/bju.15824.
    PubMed    


  30. HARVEY M, Ong WL, Chao M, Udovicich C, et al
    Comprehensive review of hydrogel spacers prior to radiation therapy for prostate cancer.
    BJU Int. 2022 Jun 10. doi: 10.1111/bju.15821.
    PubMed     Abstract available


  31. LANGLEY S, Eden C, Perry M, Patil K, et al
    Robot-assisted salvage seminal vesicle excision for isolated recurrence after low-dose-rate prostate brachytherapy.
    BJU Int. 2022;129:731-736.
    PubMed     Abstract available


  32. LAWRENTSCHUK N
    Sensible government decisions on funding for imaging can change practice and deliver better care for men with prostate cancer.
    BJU Int. 2022;130 Suppl 1:4.
    PubMed    


  33. PERRY E, Talwar A, Taubman K, Ng M, et al
    Pathological predictors of (18) F-DCFPyL prostate-specific membrane antigen-positive recurrence after radical prostatectomy.
    BJU Int. 2022;130 Suppl 1:28-36.
    PubMed     Abstract available


    May 2022
  34. O'BRIEN JS, McVey A, Kelly BD, Jenjitranant P, et al
    PSMA PET-CT Funding Grants Free Access to Superior Staging for Australian Men with Prostate Cancer.
    BJU Int. 2022 May 16. doi: 10.1111/bju.15773.
    PubMed    


  35. RAHOTA RG, Diamand R, Malavaud B, Fiard G, et al
    Pathological features of Prostate Imaging Reporting and Data System (PI-RADS) 3 MRI lesions in biopsy and radical prostatectomy specimens.
    BJU Int. 2022;129:621-626.
    PubMed     Abstract available


  36. HAYNE D, Grummet J, Espinoza D, McCombie SP, et al
    'Pain-free TRUS B': a phase 3 double-blind placebo-controlled randomized trial of methoxyflurane with periprostatic local anaesthesia to reduce the discomfort of transrectal ultrasonography-guided prostate biopsy (ANZUP 1501).
    BJU Int. 2022;129:591-600.
    PubMed     Abstract available


    April 2022
  37. NATHAN A, Morris M, Parry MG, Berry B, et al
    Interventions for obstructive uropathy in advanced prostate cancer: a population-based study.
    BJU Int. 2022 Apr 29. doi: 10.1111/bju.15766.
    PubMed     Abstract available


  38. VAN RIEL LAMJG, Geboers B, Kabaktepe E, Blazevski A, et al
    Outcomes of Salvage Radical Prostatectomy after initial IRE Treatment for Recurrent Prostate Cancer.
    BJU Int. 2022 Apr 27. doi: 10.1111/bju.15759.
    PubMed     Abstract available


  39. BOKU H, Kaneko M, Yamada Y, Morinaga Y, et al
    Microwave for focal therapy of prostate cancer: Non-clinical study and exploratory clinical trial.
    BJU Int. 2022 Apr 18. doi: 10.1111/bju.15749.
    PubMed     Abstract available


  40. LANE JA, Donovan JL, Young GJ, Davis M, et al
    Functional and quality of life outcomes of localised prostate cancer treatments (ProtecT study).
    BJU Int. 2022 Apr 3. doi: 10.1111/bju.15739.
    PubMed     Abstract available


  41. CHASE EC, Bryant AK, Sun Y, Jackson WC, et al
    Development and Validation of a Life Expectancy Calculator for U.S. Prostate Cancer Patients.
    BJU Int. 2022 Apr 3. doi: 10.1111/bju.15740.
    PubMed     Abstract available


  42. PTASZNIK G, Papa N, Kelly BD, Thompson J, et al
    High PSMA PET SUVmax in PI-RADS 4 or 5 men confers a high probability of significant prostate cancer.
    BJU Int. 2022 Apr 1. doi: 10.1111/bju.15736.
    PubMed    



  43. Prostate cancer and ethnicity, personalised treatment for renal masses and oral testosterone for hypogonadism.
    BJU Int. 2022;129:422.
    PubMed    


  44. LUZZAGO S, Piccinelli ML, Mistretta FA, Bianchi R, et al
    Repeat MRI during active surveillance: natural history of prostatic lesions and upgrading rates.
    BJU Int. 2022;129:524-533.
    PubMed     Abstract available


    March 2022

  45. New guidance regarding the diagnosis and risk stratification of patients with prostate cancer.
    BJU Int. 2022;129:304-305.
    PubMed    


  46. KLEIN RJ
    Polygenic risk scores and prostate cancer screening: a recipe for more overdiagnosis?
    BJU Int. 2022;129:271.
    PubMed    


  47. FERRARO S, Biganzoli EM
    Association between total prostate-specific antigen (tPSA), free/tPSA, and prostate cancer mortality.
    BJU Int. 2022;129:418.
    PubMed    


  48. MARTIN RM, Dixon P, Turner E, Keeney E, et al
    Contribution of the Cluster randomised triAl of PSA testing for Prostate cancer (CAP) to the ongoing debate on the value of prostate cancer screening.
    BJU Int. 2022;129:269-270.
    PubMed    


  49. TEYATEETI A, Grossman C, Kollmeier MA, Fiasconaro M, et al
    Influence of hydrogel spacer placement with prostate brachytherapy on rectal and urinary toxicity.
    BJU Int. 2022;129:337-344.
    PubMed     Abstract available


  50. BJORKLUND J, Stattin P, Ronmark E, Aly M, et al
    The 90-day cause-specific mortality after radical prostatectomy: a nationwide population-based study.
    BJU Int. 2022;129:318-324.
    PubMed     Abstract available


  51. ZHAO J, Sun G, Zhu S, Dai J, et al
    Circulating tumour DNA reveals genetic traits of patients with intraductal carcinoma of the prostate.
    BJU Int. 2022;129:345-355.
    PubMed     Abstract available


  52. PASCHEN U, Sturtz S, Fleer D, Lampert U, et al
    Assessment of prostate-specific antigen screening: an evidence-based report by the German Institute for Quality and Efficiency in Health Care.
    BJU Int. 2022;129:280-289.
    PubMed     Abstract available


    February 2022
  53. BODAR YJL, Veerman H, Meijer D, de Bie K, et al
    Standardised Uptake Values as Determined on PSMA PET/CT is associated with Oncological Outcomes in Prostate Cancer Patients.
    BJU Int. 2022 Feb 15. doi: 10.1111/bju.15710.
    PubMed     Abstract available


  54. DASON S, Vertosick EA, Udo K, Sjoberg DD, et al
    Clinical utility of subclassifying positive surgical margins at radical prostatectomy.
    BJU Int. 2022;129:194-200.
    PubMed     Abstract available


  55. SORCE G, Stabile A, Luciano R, Motterle G, et al
    Multiparametric magnetic resonance imaging of the prostate underestimates tumour volume of small visible lesions.
    BJU Int. 2022;129:201-207.
    PubMed     Abstract available


    January 2022
  56. NOSSITER J, Morris M, Parry MG, Sujenthiran A, et al
    Impact of the Covid-19 pandemic on the diagnosis and treatment of men with prostate cancer.
    BJU Int. 2022 Jan 25. doi: 10.1111/bju.15699.
    PubMed     Abstract available


  57. ONG WL, Thangasamy I, Murphy D, Pritchard E, et al
    Large variation in conservative management for low-risk prostate cancer in Australia and New Zealand.
    BJU Int. 2022 Jan 25. doi: 10.1111/bju.15698.
    PubMed    


  58. BRATT O
    Integrating magnetic resonance imaging and prostate-specific membrane antigen positron emission tomography/computed tomography results into prostate cancer treatment decision making.
    BJU Int. 2022;129:3-4.
    PubMed    


  59. GRAY WK, Day J, Briggs TWR, Harrison S, et al
    An observational study of volume-outcome effects for robot-assisted radical prostatectomy in England.
    BJU Int. 2022;129:93-103.
    PubMed     Abstract available


    December 2021
  60. RANNIKKO A, Leht M, Mirtti T, Kenttamies A, et al
    Population-based randomized trial of screening for clinically significant prostate cancer ProScreen: pilot study.
    BJU Int. 2021 Dec 27. doi: 10.1111/bju.15683.
    PubMed     Abstract available


  61. SOORIAKUMARAN P, Wilson C, Rombach I, Hassanali N, et al
    Feasibility and safety of radical prostatectomy for oligo-metastatic prostate cancer: TRoMbone trial.
    BJU Int. 2021 Dec 8. doi: 10.1111/bju.15669.
    PubMed     Abstract available


  62. VEERMAN H, Donswijk M, Bekers E, Olde Heuvel J, et al
    Clinical Characteristics of Primary Non-PSMA-Expressing Prostate Cancer on preoperative PSMA PET/CT.
    BJU Int. 2021 Dec 1. doi: 10.1111/bju.15664.
    PubMed     Abstract available



  63. Acute Urinary Retention and Cancer; Is It All About the Prostate?
    BJU Int. 2021;128:660.
    PubMed    


  64. LENFANT L, Corrigan D, Beksac AT, Schwen Z, et al
    Learning curve analysis of single-port robot-assisted extraperitoneal prostatectomy using the cumulative sum (CUSUM) method.
    BJU Int. 2021;128:688-691.
    PubMed    


  65. SANDAHL M, Pedersen BG, Ulhoi BP, Borre M, et al
    Risk stratification in men with a negative prostate biopsy: an interim analysis of a prospective cohort study.
    BJU Int. 2021;128:702-712.
    PubMed     Abstract available


  66. HENNES DMZB, Sewell J, Kerger M, Hovens CM, et al
    The modified International Society of Urological Pathology system improves concordance between biopsy and prostatectomy tumour grade.
    BJU Int. 2021;128 Suppl 3:45-51.
    PubMed     Abstract available


    November 2021
  67. JOHN JB, Pascoe J, Fowler S, Walton T, et al
    A nationwide trend away from radical prostatectomy for Gleason grade group 1 prostate cancer.
    BJU Int. 2021 Nov 26. doi: 10.1111/bju.15656.
    PubMed     Abstract available


  68. ROSENBERG JE, Jung JH, Lee H, Lee S, et al
    Posterior musculofascial reconstruction in robotic-assisted laparoscopic prostatectomy for the treatment of clinically localized prostate cancer: a Cochrane Review.
    BJU Int. 2021 Nov 26. doi: 10.1111/bju.15657.
    PubMed     Abstract available


  69. LEE V, An Y, Park HS, Yu JB, et al
    Emergency Department Visits for Radiation Cystitis Among Patients with a Prostate Cancer History.
    BJU Int. 2021 Nov 22. doi: 10.1111/bju.15650.
    PubMed     Abstract available


  70. KANNAN A, Clouston D, Frydenberg M, Ilic D, et al
    Neuroendocrine cells in prostate cancer correlate with poor outcomes: A systematic review and meta-analysis.
    BJU Int. 2021 Nov 16. doi: 10.1111/bju.15647.
    PubMed     Abstract available


  71. HOFBAUER SL, Luger F, Harland N, Plage H, et al
    A Non-Inferiority Comparative Analysis of Micro-Ultrasound and MRI Targeted Biopsy in Men at Risk of Prostate Cancer.
    BJU Int. 2021 Nov 13. doi: 10.1111/bju.15635.
    PubMed     Abstract available


  72. IP CCK, Kealey J, Davis ID, Sengupta S, et al
    Impacts of the COVID-19 Pandemic on Early Detection of Prostate Cancer in Australia.
    BJU Int. 2021 Nov 9. doi: 10.1111/bju.15631.
    PubMed     Abstract available


  73. HEESTERMAN BL, van der Poel HG, Schoots IG, Mehra N, et al
    Prognostic importance of concomitant non-regional lymph node and bone metastases in men with newly diagnosed metastatic prostate cancer.
    BJU Int. 2021 Nov 6. doi: 10.1111/bju.15632.
    PubMed     Abstract available


  74. PALUDO AO, Knijnik PG, Silva Neto B, Berger M, et al
    Initial experience with first postoperative day Foley catheter removal after robot-assisted radical prostatectomy.
    BJU Int. 2021;128:555-557.
    PubMed    


  75. TULLY KH, Schulmeyer M, Hanske J, Reike MJ, et al
    Identification of patients at risk for biochemical recurrence after radical prostatectomy with intra-operative frozen section.
    BJU Int. 2021;128:598-606.
    PubMed     Abstract available


  76. ZHANG Z, Lampotang S, Yu Y, Acar YA, et al
    Attitude is everything: keep probe pitch neutral during side-fire prostate biopsy. A simulator study.
    BJU Int. 2021;128:615-624.
    PubMed     Abstract available


    October 2021
  77. HUYNH LM, Huang E, Towe M, Liang K, et al
    Evidence for integration of total and free testosterone levels in management of prostate cancer.
    BJU Int. 2021 Oct 30. doi: 10.1111/bju.15626.
    PubMed     Abstract available


  78. POULIOT F, Beauregard JM, Saad F, Trudel D, et al
    The 3TMPO study protocol: triple-tracer PET imaging of metastatic castration-resistant prostate cancer.
    BJU Int. 2021 Oct 21. doi: 10.1111/bju.15621.
    PubMed     Abstract available


  79. WITT JH, Friedrich M, Jandrig B, Porsch M, et al
    Molecular margin status after radical prostatectomy using glutathione S-transferase P1 (GSTP1) promoter hypermethylation.
    BJU Int. 2021 Oct 17. doi: 10.1111/bju.15618.
    PubMed     Abstract available


  80. MARRA G, Calleris G, Marquis A, Oderda M, et al
    Reply to letter by Montorsi et al. Re: Marra et al. 'Transperineal freehand multiparametric MRI fusion targeted biopsies under local anaesthesia for prostate cancer diagnosis: a multicentre prospective study of 1014 cases'.
    BJU Int. 2021;128:524.
    PubMed    


  81. MONTORSI F, Stabile A, Gandaglia G, Fossati N, et al
    Re: Marra et al. 'Transperineal freehand multiparametric MRI fusion targeted biopsies under local anaesthesia for prostate cancer diagnosis: a multicentre prospective study of 1014 cases'.
    BJU Int. 2021;128:523.
    PubMed    


  82. GULDBAEK MV, Fode M, Jensen CFS, Sonksen J, et al
    'Case of the Month' from Herlev and Gentofte Hospital, Denmark: metastatic prostate cancer in a man with late-onset hypogonadism following testosterone-replacement therapy.
    BJU Int. 2021;128:428-430.
    PubMed    


  83. KELLY R, Anton A, Wong S, Shapiro J, et al
    Real-world use of first-generation antiandrogens: impact on patient outcomes and subsequent therapies in metastatic castration-resistant prostate cancer.
    BJU Int. 2021;128 Suppl 1:18-26.
    PubMed     Abstract available


  84. CATHCART P, Ribeiro L, Moore C, Ahmed HU, et al
    Outcomes of the RAFT trial: robotic surgery after focal therapy.
    BJU Int. 2021;128:504-510.
    PubMed     Abstract available


    September 2021
  85. LIGHT A, Burns-Cox N, Maccormick A, John J, et al
    The diagnostic impact of UK regional variations in age-specific prostate-specific antigen guidelines.
    BJU Int. 2021;128:298-300.
    PubMed    


    August 2021
  86. URIBE-LEWIS S, Uribe J, Bourke V, Deering C, et al
    Long-term survival after LDR Brachytherapy for Prostate Cancer: the Royal Surrey experience.
    BJU Int. 2021 Aug 27. doi: 10.1111/bju.15585.
    PubMed     Abstract available


  87. MOROTE J, Schwartzmann I, Celma A, Roche S, et al
    The current recommendation for the management of isolated high-grade prostatic intraepithelial neoplasia.
    BJU Int. 2021 Aug 10. doi: 10.1111/bju.15568.
    PubMed     Abstract available


  88. DOAN P, Graham P, Lahoud J, Remmers S, et al
    A comparison of prostate cancer prediction models in men undergoing both magnetic resonance imaging and transperineal biopsy: Are the models still relevant?
    BJU Int. 2021 Aug 9. doi: 10.1111/bju.15554.
    PubMed     Abstract available


  89. ISRAEL B, Immerzeel J, van der Leest M, Hannink G, et al
    Clinical Implementation of Pre-biopsy MRI-Pathways for the Diagnosis of Prostate Cancer.
    BJU Int. 2021 Aug 6. doi: 10.1111/bju.15562.
    PubMed     Abstract available



  90. FDA approves a second PSMA targeting agent for PET imaging in men with prostate cancer.
    BJU Int. 2021;128:127-130.
    PubMed    


  91. DUDDERIDGE TJ
    Multiparametric magnetic resonance imaging - a crucial imaging tool for considering and planning prostate cancer focal therapy.
    BJU Int. 2021;128:125-126.
    PubMed    


  92. INOUE T, Sasaki T, Kato M, Masui S, et al
    Warning against second-generation antiandrogen for metastatic castration sensitive prostate cancer.
    BJU Int. 2021 Aug 1. doi: 10.1111/bju.15561.
    PubMed     Abstract available



  93. Chemotherapeutic treatment of MCRPC and non-MCRPC.
    BJU Int. 2021;128:153-154.
    PubMed    


  94. TAMIR S, Hermann D, Margel D, Gavrielli S, et al
    Indications for prostate multiparametric magnetic resonance imaging: changes over 7 years in a single referral centre.
    BJU Int. 2021;128:165-167.
    PubMed    


    July 2021
  95. BUELENS S, Poelaert F, Claeys T, De Bleser E, et al
    Multicentric Prospective Local Treatment of Metastatic Prostate Cancer (LoMP) Study.
    BJU Int. 2021 Jul 21. doi: 10.1111/bju.15553.
    PubMed     Abstract available


  96. KAMRAN SC, Zietman AL
    Radiation Treatment in Prostate Cancer: Covering the Waterfront.
    BJU Int. 2021 Jul 17. doi: 10.1111/bju.15550.
    PubMed     Abstract available


  97. KREIS K, Horenkamp-Sonntag D, Schneider U, Zeidler J, et al
    Safety and survival of docetaxel and cabazitaxel in metastatic castration-resistant prostate cancer.
    BJU Int. 2021 Jul 9. doi: 10.1111/bju.15542.
    PubMed     Abstract available


  98. BENAFIF S, Ni Raghallaigh H, McGrowder E, Saunders EJ, et al
    The BARCODE1 Pilot: a feasibility study of using germline SNPs to target prostate cancer screening.
    BJU Int. 2021 Jul 2. doi: 10.1111/bju.15535.
    PubMed     Abstract available


  99. MOTTRIE A, Mazzone E, Wiklund P, Graefen M, et al
    Objective assessment of intraoperative skills for robot-assisted radical prostatectomy (RARP): results from the ERUS Scientific and Educational Working Groups Metrics Initiative.
    BJU Int. 2021;128:103-111.
    PubMed     Abstract available


  100. SINGH S, Sandhu P, Beckmann K, Santaolalla A, et al
    Negative first follow-up prostate biopsy on active surveillance is associated with decreased risk of upgrading, suspicion of progression and converting to active treatment.
    BJU Int. 2021;128:72-78.
    PubMed     Abstract available


    June 2021
  101. MORI K, Mostafaei H, Sari Motlagh R, Pradere B, et al
    Systemic Therapies for Metastatic Hormone-Sensitive Prostate Cancer: Network Meta-Analysis.
    BJU Int. 2021 Jun 25. doi: 10.1111/bju.15507.
    PubMed     Abstract available


  102. BERTONCELLI TANAKA M, Sahota K, Burn J, Falconer A, et al
    Prostate cancer in transgender women: what does a urologist need to know?
    BJU Int. 2021 Jun 22. doi: 10.1111/bju.15521.
    PubMed     Abstract available


  103. ALBERTSEN P
    Prostate cancer: the interplay between genetics and the environment.
    BJU Int. 2021;127:615-616.
    PubMed    


  104. YAXLEY J
    Letter to the Editor BJUI in response to Montorsi et al.: Histological comparison between predictive value of preoperative 3-T multiparametric MRI and (68) Ga-PSMA PET/CT scan for pathological outcomes at radical prostatectomy and pelvic lymph node di
    BJU Int. 2021;127:747.
    PubMed    


  105. DIRIE J, Mahesan T, Hart E, Janardanan S, et al
    Delivering safe and timely cancer care during COVID-19: lessons and successes from the transition period.
    BJU Int. 2021;127:633-635.
    PubMed    


  106. TANDOGDU Z, Collins J, Shaw G, Rohn J, et al
    Management of patients who opt for radical prostatectomy during the coronavirus disease 2019 (COVID-19) pandemic: an international accelerated consensus statement.
    BJU Int. 2021;127:729-741.
    PubMed     Abstract available


  107. DINNEEN E, Haider A, Grierson J, Freeman A, et al
    NeuroSAFE frozen section during robot-assisted radical prostatectomy: peri-operative and histopathological outcomes from the NeuroSAFE PROOF feasibility randomized controlled trial.
    BJU Int. 2021;127:676-686.
    PubMed     Abstract available


    May 2021
  108. EMMETT L, Subramaniam S, Joshua A, Crumbaker M, et al
    ENZA-p trial protocol: A randomised phase II trial using PSMA as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).
    BJU Int. 2021 May 24. doi: 10.1111/bju.15491.
    PubMed     Abstract available


  109. MEIJER D, van Leeuwen PJ, Donswijk ML, Boellaard TN, et al
    Predicting Early Outcomes in Intermediate and High Risk Prostate Cancer Patients using PSMA PET and MRI.
    BJU Int. 2021 May 24. doi: 10.1111/bju.15492.
    PubMed     Abstract available


  110. KNIPPER S, Tilki D, Graefen M, Maurer T, et al
    Early prostate cancer recurrence with PSMA PET positive unilateral pelvic lesion(s): is one-sided salvage extended lymph node dissection enough? (ProSTone, NCT04271579).
    BJU Int. 2021 May 22. doi: 10.1111/bju.15485.
    PubMed     Abstract available


  111. O'CALLAGHAN M, Papa N, Pase M, Frydenberg M, et al
    Patterns of care for prostate cancer treatment and improving outcomes - are national registries the answer?
    BJU Int. 2021 May 11. doi: 10.1111/bju.15366.
    PubMed    



  112. Recent advances in the diagnosis and management of prostate cancer.
    BJU Int. 2021;127:518-519.
    PubMed    


  113. URKMEZ A, Ward JF, Choi H, Troncoso P, et al
    Temporal learning curve of a multidisciplinary team for magnetic resonance imaging/transrectal ultrasonography fusion prostate biopsy.
    BJU Int. 2021;127:524-527.
    PubMed    


  114. INOUE S, Hayashi T, Teishima J, Matsubara A, et al
    Longitudinal evaluation of the frequency of sexual intercourse and sexual activity in patients after nerve-sparing robot-assisted laparoscopic radical prostatectomy.
    BJU Int. 2021;127:560-566.
    PubMed     Abstract available


  115. TUTOLO M, Bruyneel L, Van der Aa F, Van Damme N, et al
    A novel tool to predict functional outcomes after robot-assisted radical prostatectomy and the value of additional surgery for incontinence.
    BJU Int. 2021;127:575-584.
    PubMed     Abstract available


  116. TIMM B, Farag M, Liodakis P, Angus D, et al
    Vesico-urethral anastomosis sampling: a forgotten tool for guiding salvage radiation after radical prostatectomy.
    BJU Int. 2021;127 Suppl 1:23-29.
    PubMed     Abstract available


  117. JOHN A, John H, Catterwell R, Selth LA, et al
    Primary Gleason grade and Gleason grade group at positive surgical margins: a systematic review and meta-analysis.
    BJU Int. 2021;127 Suppl 1:13-22.
    PubMed     Abstract available


    April 2021
  118. CHILUKURI S, Murthy V
    Adjuvant radiation for prostate cancer: Too early to abandon?
    BJU Int. 2021 Apr 9. doi: 10.1111/bju.15422.
    PubMed     Abstract available


  119. LUNDGREN PO, Kjellman A, Norming U, Gustafsson O, et al
    Association Between One-time Prostate-Specific Antigen (PSA) Test with Free/Total PSA and Prostate Cancer Mortality: A 30-year Prospective Cohort Study.
    BJU Int. 2021 Apr 3. doi: 10.1111/bju.15417.
    PubMed     Abstract available


  120. XU AJ, Taylor J, Gao T, Mihalcea R, et al
    TikTok and Prostate Cancer: Misinformation and Quality of Information using Validated Questionnaires.
    BJU Int. 2021 Apr 2. doi: 10.1111/bju.15403.
    PubMed     Abstract available


  121. GALFANO A, Secco S, Dell'Oglio P, Rha K, et al
    Retzius-sparing robot-assisted radical prostatectomy: early learning curve experience in three continents.
    BJU Int. 2021;127:412-417.
    PubMed     Abstract available


    March 2021
  122. BARRETT T, Padhani AR, Patel A, Ahmed HU, et al
    Certification in reporting multiparametric magnetic resonance imaging of the prostate: recommendations of a UK consensus meeting.
    BJU Int. 2021;127:304-306.
    PubMed    


  123. NYBERG M, Sjoberg DD, Carlsson SV, Wilderang U, et al
    Surgeon heterogeneity significantly affects functional and oncological outcomes after radical prostatectomy in the Swedish LAPPRO trial.
    BJU Int. 2021;127:361-368.
    PubMed     Abstract available


    February 2021
  124. HUANG MM, Su ZT, Becker REN, Pavlovich CP, et al
    Complications after open and robot-assisted radical prostatectomy and association with postoperative opioid use: an analysis of data from the PREVENTER trial.
    BJU Int. 2021;127:190-197.
    PubMed     Abstract available


    January 2021
  125. AHO T, Al-Hayek S, Winterbottom A, Koo B, et al
    'Case of the Month' from Cambridge University, UK: managing intractable bleeding from a 375 cc prostate in an anti-coagulated patient.
    BJU Int. 2021;127:37-40.
    PubMed    



  126. World News.
    BJU Int. 2021;127:1-3.
    PubMed    


  127. COVAS MOSCHOVAS M, Bhat S, Onol F, Rogers T, et al
    Early outcomes of single-port robot-assisted radical prostatectomy: lessons learned from the learning-curve experience.
    BJU Int. 2021;127:114-121.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: